Background Chronic oral quercetin reduces blood pressure and restores endothelial dysfunction in hypertensive animals. However, quercetin (aglycone) is usually not present in plasma, because it is rapidly metabolized into conjugated, mostly inactive, metabolites. The aim of the study is to analyze whether deconjugation of these metabolites is involved in the blood pressure lowering effect of quercetin. Methodology/Principal Findings We have analyzed the effects on blood pressure and vascular function in vitro of the conjugated metabolites of quercetin (quercetin-3-glucuronide, Q3GA; isorhamnetin-3-glucuronide, I3GA; and quercetin-3′-sulfate, Q3'S) in spontaneously hypertensive rats (SHR). Q3GA and I3GA (1 mg/kg i.v.), but not Q3'S, progressively reduced mean blood pressure (MBP), measured in conscious SHR. The hypotensive effect of Q3GA was abolished in SHR treated with the specific inhibitor of β-glucuronidase, saccharic acid 1,4-lactone (SAL, 10 mg/ml). In mesenteric arteries, unlike quercetin, Q3GA had no inhibitory effect in the contractile response to phenylephrine after 30 min of incubation. However, after 1 hour of incubation Q3GA strongly reduced this contractile response and this effect was prevented by SAL. Oral administration of quercetin (10 mg/Kg) induced a progressive decrease in MBP, which was also suppressed by SAL. Conclusions Conjugated metabolites are involved in the in vivo antihypertensive effect of quercetin, acting as molecules for the plasmatic transport of quercetin to the target tissues. Quercetin released from its glucuronidated metabolites could be responsible for its vasorelaxant and hypotensive effect.
References
[1]
Hertog MG, Hollman PC, Katan MB, Kromhout D (1993) Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20: 21–29.
[2]
Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB (2002) Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 102: 1414–1420.
[3]
Hertog MG, Feskens EJM, Hollman PCH, Katan MB, Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007–1111.
[4]
Keli SO, Hertog MGL, Feskens EJM, Kromhout D (1996) Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 156: 637–642.
[5]
Perez-Vizcaino F, Duarte J (2010) Flavonols and cardiovascular disease. Mol Aspects Med 31: 478–494.
[6]
Gryglewski RJ, Korbut R, Robak J, Swies J (1987) On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 36: 317–322.
[7]
Duarte J, Perez-Vizcaino F, Zarzuelo A, Jimenez J, Tamargo J (1993) Vasodilator effects of quercetin on isolated rat vascular smooth muscle. Eur J Pharmacol 239: 1–7.
[8]
Pérez-Vizcaíno F, Ibarra M, Cogolludo AL, Duarte J, Zaragozá-Arnáez F, et al. (2002) Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J Pharmacol Exp Ther 302: 66–72.
[9]
Duarte J, Pérez-Palencia R, Vargas F, Ocete MA, Pérez-Vizcaino F, et al. (2001) Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 133: 117–124.
[10]
Sánchez M, Galisteo M, Vera R, Villar IC, Zarzuelo A, et al. (2006) Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction inspontaneously hypertensive rats. J Hypertens 24: 75–84.
[11]
Machha A, Mustafa MR (2005) Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol 46: 36–40.
[12]
Romero M, Jiménez R, Hurtado B, Moreno JM, Rodríguez-Gómez I, et al. (2010) Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur J Pharmacol 627: 242–250.
[13]
Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, et al. (2007) Quercetin reduces blood pressure in hypertensive subjects. J Nutr 137: 2405–2411.
[14]
Kroon PA, Clifford MN, Crozier A (2004) How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr 80: 15–21.
[15]
Manach C, Morand C, Crespy V (1998) Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 24: 331–336.
[16]
Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130: 2073S–2085S.
[17]
Day AJ, Mellon F, Barron D, Sarrazin G, Morgan MR, et al. (2001) Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 35: 941–952.
[18]
Mullen W, Edwards CA, Crozier A (2006) Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr 96: 107–116.
[19]
Williamson G, Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81: 243S–255S.
[20]
Lodi F, Jiménez R, Menendez C, Needs PW, Duarte J, et al. (2008) Glucuronidated metabolites of the flavonoid quercetin do not auto-oxidise, do not generate free radicals and do not decrease nitric oxide bioavailability. Planta Med 74: 741–746.
[21]
Lodi F, Jimenez R, Moreno L, Kroon PA, Needs PW, et al. (2009) Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis 204: 34–39.
[22]
Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, et al. (2008) Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 283: 9424–9434.
[23]
O'Leary KA, Day AJ, Needs PW, Sly WS, O'Brien NM, et al. (2001) Flavonoid glucuronides are substrates for human liver beta-glucuronidase. FEBS Lett 503: 103–106.
[24]
Menendez C, Due？as M, Galindo P, González-Manzano S, Jimenez R, et al. (2011) Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed? Mol Nutr Food Res 55: 1780–1790.
[25]
Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ (2004) Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol 130: 388–394.
[26]
Mulvany MJ, Halpern W (1997) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19–26.
[27]
Due？as M, Mingo-Chornet H, Pérez-Alonso JJ, Di Paola-Naranjo R, González-Manzano AM, et al. (2008) Preparation of quercetin glucuronides and characterization by HPLC-DAD-ESI/MS. Eur Food Res Technol 227: 1069–1076.
[28]
Jones DJL, Jukes-Jones R, Verschoyle RD, Farmer PB, Gescher A (2005) A synthetic approach to the generation of quercetin sulfates and the detection of quercetin 3′-O-sulfate as a urinary metabolite in the rat. Bioorgan Med Chem 13: 6727–6731.
[29]
Plumb GW, O'Leary K, Day AJ, Williamson G (2003) Methods in polyphenol analysis. Santos-Buelga C, Williamson G, editors. 177 p. The Royal Society of Chemistry. Cambridge.
Galisteo M, García-Saura MF, Jiménez R, Villar IC, Wangensteen R, et al. (2004) Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil. Planta Med 70: 334–341.
[32]
García-Saura MF, Galisteo M, Villar IC, Bermejo A, Zarzuelo A, et al. (2005) Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem 270: 147–155.
[33]
Aoi W, Niisato N, Miyazaki H, Marunaka Y (2004) Flavonoid-induced reduction of ENaC expression in the kidney of Dahl salt-sensitive hypertensive rat. Biochem Biophys Res Commun 315: 892–896.
[34]
Jalili T, Carlstrom J, Kim S, Freeman D, Jin H, et al. (2006) Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol 47: 531–541.
[35]
Yamamoto Y, Oue E (2006) Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci Biotechnol Biochem 70: 933–939.
[36]
Mackraj I, Govender T, Ramesar S (2008) The antihypertensive effects of quercetin in a salt-sensitive model of hypertension. J Cardiovasc Pharmacol 51: 239–245.
[37]
Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, et al. (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 102: 1065–1074.
[38]
Manach C, Texier O, Morand C, Crespy V, Régérat F, et al. (1999) Comparison of the bioavailability of quercetin and catechin in rats. Free Radic Biol Med 27: 1259–1266.
[39]
da Silva EL, Piskula MK, Yamamoto N, Moon JH, Terao J (1998) Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. FEBS Lett 430: 405–408.
[40]
Duarte J, Pérez-Vizcaíno F, Zarzuelo A, Jiménez J, Tamargo J (1994) Inhibitory effects of quercetin and staurosporine on phasic contractions in rat vascular smooth muscle. Eur J Pharmacol 262: 149–156.
[41]
Cogolludo A, Frazziano G, Briones AM, Cobe？o L, Moreno L, et al. (2007) The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H2O2. Role in vasodilatation. Cardiovasc Res 73: 424–31.
[42]
Khoo NK, White CR, Pozzo-Miller L, Zhou F, Constance C, et al. (2010) Dietary flavonoid quercetin stimulates vasorelaxation in aortic vessels. Free Radic Biol Med 49: 339–347.
[43]
Nyborg NC, Bevan JA (1988) Increased alpha-adrenergic receptor affinity in resistance vessels from hypertensive rats. Hypertension 11: 635–638.
[44]
Nomura Y, Asano M (2002) Increased Ca2+ buffering function of sarcoplasmic reticulum in small mesenteric arteries from spontaneously hypertensive rats. Hypertens Res 25: 231–239.
[45]
Moon JH, Tsushida T, Nakahara K, Terao J (2001) Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 30: 1274–1285.
[46]
Lotito SB, Frei B (2006) Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 41: 1727–1746.
[47]
Mochizuki M, Kajiya K, Terao J, Kaji K, Kumazawa S, et al. (2004) Effect of quercetin conjugates on vascular permeability and expression of adhesion molecules. Biofactors 22: 201–204.
[48]
Shimoi K, Saka N, Nozawa R, Sato M, Amano I, et al. (2001) Deglucuronidation of a flavonoid luteolin monoglucuronide during inflammation. Drug Metab Dispos 29: 1521–1524.
[49]
Michihara A, Toda K, Kubo T, Fujiwara Y, Akasaki K, et al. (2005) Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull 28: 947–951.
[50]
Sullivan JC, Semprun-Prieto L, Boesen EI, Pollock DM, Pollock JS (2007) Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 293: R1573–R1579.
[51]
Li L, Yi-Ming W, Li ZZ, Zhao L, Yu YS, et al. (2008) Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats. Pharmacol Res 58: 196–201.
[52]
Schewe T, Steffen Y, Sies H (2008) How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys 476: 102–106.
[53]
Crettol S, Petrovic N, Murray M (2010) Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 16: 204–219.
